BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCommercial

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the

Related news

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

ECORelectroCore2026-06-09 12:00 EST

Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery

TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

ECORelectroCore2026-06-02 12:00 EST

electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

TNXPTonix Pharmaceuticals2026-06-11 11:00 EST

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

CRNXCrinetics Pharmaceuticals2026-06-02 20:05 EST

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

TEVATeva Pharmaceutical Industries2026-06-10 16:03 EST

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-23 20:05 EST

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

NBIXNeurocrine Biosciences2026-07-21 20:05 EST

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Stock data

Close
159.82 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States